Assoc Prof Rebecca Lim is an experienced cell biologist having spanned two decades in academia and biotech, focusing on cell therapies for urgent unmet medical needs. Her academic research was focused on regenerative medicine and allogeneic cell therapies (primarily amniotic epithelial cells) and their extracellular vesicles for diseases such as bronchopulmonary dysplasia, acute ischaemic stroke, compensated liver cirrhosis and Crohn's related perianal fistulas, all of which were translated into Phase 1 clinical trials.

In 2021, A/Prof Lim transitioned to biotech as the Senior VP for Scientific Affairs at Prescient Therapeutics. In this role, she led the development of a modular CAR-T program involving several collaborations with academia (Peter MacCallum Cancer Center) and industry collaborations (Thermo Fisher Scientific). 

More recently, she is applying her experience in R&D and clinical translation to clinical stage projects at MD Anderson Cancer Center where she leads strategic partnerships with biotech companies at CTMC in Houston, Texas as Director, Project and Alliance Leadership.